Abstract

BackgroundThe biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ.ObjectivesTo determine the association of CXCL13 and sICAM1 with response to TCZ and disease...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
Michael J Townsend ... Ruediger Paul Laubender
Advances in Rheumatology | VOL. 59
Michael J Townsend, et. al.Michael J Townsend ... Ruediger Paul Laubender
01 Dec 2019
SAT0116 The study of baseline serum sicam-1 and cxcl13 levels in predicting response to tumor necrosis factor-Α inhibitor therapy in patients with rheumatoid arthritis
J Zhao ... X Ye
Annals of the Rheumatic Diseases | VOL. 77
J Zhao, et. al.J Zhao ... X Ye
01 Jun 2018
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs
Serena Bugatti ... Antonio Manzo
Annals of the Rheumatic Diseases | VOL. 71
Serena Bugatti, et. al.Serena Bugatti ... Antonio Manzo
01 Feb 2012
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
Roberto Caporali ... Serena Bugatti
Arthritis Research & Therapy | VOL. 14
Roberto Caporali, et. al.Roberto Caporali ... Serena Bugatti
01 Jan 2012
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers